268 related articles for article (PubMed ID: 14737948)
1. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients.
Kozłowski L; Zakrzewska I; Tokajuk P; Wojtukiewicz MZ
Rocz Akad Med Bialymst; 2003; 48():82-4. PubMed ID: 14737948
[TBL] [Abstract][Full Text] [Related]
2. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival.
Benoy IH; Salgado R; Van Dam P; Geboers K; Van Marck E; Scharpé S; Vermeulen PB; Dirix LY
Clin Cancer Res; 2004 Nov; 10(21):7157-62. PubMed ID: 15534087
[TBL] [Abstract][Full Text] [Related]
3. [The value of plasma interleukin-6 and interleukin-8 in monitoring of patients with breast cancer].
Zakrzewska I; Omyła J
Pol Merkur Lekarski; 2005 Apr; 18(106):424-6. PubMed ID: 16161926
[TBL] [Abstract][Full Text] [Related]
4. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
Zhang GJ; Adachi I
Anticancer Res; 1999; 19(2B):1427-32. PubMed ID: 10365118
[TBL] [Abstract][Full Text] [Related]
5. Reduction in serum IL-6 after vacination of breast cancer patients with tumour-associated antigens is related to estrogen receptor status.
Jiang XP; Yang DC; Elliott RL; Head JF
Cytokine; 2000 May; 12(5):458-65. PubMed ID: 10857759
[TBL] [Abstract][Full Text] [Related]
6. [The levels of selected cytokines in patients with colorectal cancer--a preliminary report].
Grotowski M; Piechota W
Pol Merkur Lekarski; 2001 Oct; 11(64):327-9. PubMed ID: 11770312
[TBL] [Abstract][Full Text] [Related]
7. Relationship between IL-10 and tumor markers in breast cancer patients.
Llanes-Fernández L; Alvarez-Goyanes RI; Arango-Prado Mdel C; Alcocer-González JM; Mojarrieta JC; Pérez XE; López MO; Odio SF; Camacho-Rodríguez R; Guerra-Yi ME; Madrid-Marina V; Tamez-Guerra R; Rodríguez-Padilla C
Breast; 2006 Aug; 15(4):482-9. PubMed ID: 16403632
[TBL] [Abstract][Full Text] [Related]
8. Immune and endocrine mechanisms of advanced cancer-related hypercortisolemia.
Lissoni P; Brivio F; Fumagalli L; Messina G; Secreto G; Romelli B; Fumagalli G; Rovelli F; Colciago M; Brera G
In Vivo; 2007; 21(4):647-50. PubMed ID: 17708360
[TBL] [Abstract][Full Text] [Related]
9. Serum evaluation of interleukin 6 in ovarian cancer patients.
Tempfer C; Zeisler H; Sliutz G; Haeusler G; Hanzal E; Kainz C
Gynecol Oncol; 1997 Jul; 66(1):27-30. PubMed ID: 9234916
[TBL] [Abstract][Full Text] [Related]
10. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma.
Snoussi K; Strosberg AD; Bouaouina N; Ben Ahmed S; Chouchane L
Eur Cytokine Netw; 2005 Dec; 16(4):253-60. PubMed ID: 16464738
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma.
Hsia CY; Huo TI; Chiang SY; Lu MF; Sun CL; Wu JC; Lee PC; Chi CW; Lui WY; Lee SD
Eur J Surg Oncol; 2007 Mar; 33(2):208-12. PubMed ID: 17140760
[TBL] [Abstract][Full Text] [Related]
12. Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma.
Nacinović-Duletić A; Stifter S; Dvornik S; Skunca Z; Jonjić N
Int J Lab Hematol; 2008 Jun; 30(3):230-9. PubMed ID: 18479302
[TBL] [Abstract][Full Text] [Related]
13. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy.
Bozcuk H; Uslu G; Samur M; Yildiz M; Ozben T; Ozdoğan M; Artaç M; Altunbaş H; Akan I; Savaş B
Cytokine; 2004 Jul 21-Aug 7; 27(2-3):58-65. PubMed ID: 15242694
[TBL] [Abstract][Full Text] [Related]
14. Changes of cytokines and thyroid function in patients with recurrent breast cancer.
Yokoe T; Iino Y; Takei H; Horiguchi J; Koibuchi Y; Maemura M; Ohwada S; Morishita Y
Anticancer Res; 1997; 17(1B):695-9. PubMed ID: 9066604
[TBL] [Abstract][Full Text] [Related]
15. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions.
Coskun U; Bukan N; Sancak B; Günel N; Ozenirler S; Unal A; Yucel A
Neoplasma; 2004; 51(3):209-13. PubMed ID: 15254675
[TBL] [Abstract][Full Text] [Related]
16. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis.
Ebrahimi B; Tucker SL; Li D; Abbruzzese JL; Kurzrock R
Cancer; 2004 Dec; 101(12):2727-36. PubMed ID: 15526319
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study.
Mustea A; Braicu EI; Koensgen D; Yuan S; Sun PM; Stamatian F; Lichtenegger W; Chen FC; Chekerov R; Sehouli J
Cytokine; 2009 Jan; 45(1):8-11. PubMed ID: 19071030
[TBL] [Abstract][Full Text] [Related]
18. [Value of interleukin-8 determination in diagnosis of benign and malignant breast tumor].
Zakrzewska I; Kozłowski L; Wojtukiewicz M
Pol Merkur Lekarski; 2002 Oct; 13(76):302-4. PubMed ID: 12557436
[TBL] [Abstract][Full Text] [Related]
19. Significance of inflammatory cytokines in the progression of colorectal cancer.
Chung YC; Chang YF
Hepatogastroenterology; 2003; 50(54):1910-3. PubMed ID: 14696431
[TBL] [Abstract][Full Text] [Related]
20. [Interleukin-6 and its soluble receptors in human breast cancer].
Kuang Y; Zhang Z; Zhang X
Zhonghua Zhong Liu Za Zhi; 1998 Jul; 20(4):305-7. PubMed ID: 10920992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
